Physician profile
Sam P Smith
NPI 1962420315
$39,128.21
in general payments reported to CMS, 2019-2025
37 companies · $2,188 in 2025
The $2,188 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $6,301 · 2021: $7,671 · 2022: $4,630 · 2023: $4,433 · 2024: $3,348 · 2025: $2,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,614 · Consulting Fee: $1,240 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,613.96 |
| Consulting Fee | $1,240.00 |
| Education | $114.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $10,001.49 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Leo Pharma INC. | $6,940.64 | 2019-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $6,544.12 | 2019-2025 | Jublia, Siliq, Targretin |
| Pfizer INC. | $4,535.12 | 2019-2025 | |
| Abbvie INC. | $2,019.58 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,250.05 | 2019-2024 | Tremfya, Simponi Aria, Stelara |
| Dermavant Sciences, INC. | $1,167.92 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $1,029.36 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $771.57 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $719.82 | 2023-2025 | Opzelura |
| Amgen INC. | $681.42 | 2020-2025 | Otezla |
| Novartis Pharmaceuticals Corporation | $671.18 | 2019-2025 | |
| Ucb, INC. | $499.81 | 2019-2025 | Bimzelx, Cimzia |
| Epi Health, LLC | $404.91 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $269.64 | 2023-2025 | Zoryve |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $239.83 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $223.99 | 2019-2025 | |
| Galderma Laboratories, L.P. | $211.68 | 2021-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $164.18 | 2022-2024 | Sotyktu |
| Intersect Ent, INC. | $115.31 | 2019 | |
| Organon LLC | $97.28 | 2025 | Vtama |
| Dermira, INC. | $88.61 | 2019-2021 | |
| Almirall LLC | $82.27 | 2019-2022 | |
| Kyowa Kirin, INC. | $52.43 | 2023-2025 | Poteligeo |
| Merz North America, INC. | $48.46 | 2021 | |
| Biofrontera INC. | $40.34 | 2021-2022 | |
| Celgene Corporation | $39.25 | 2019 | |
| Fresenius Kabi USA, LLC | $33.37 | 2023 | |
| Prugen, INC. Pharmaceuticals | $30.44 | 2019-2020 | |
| Strata Skin Sciences, INC. | $28.91 | 2025 | Xtrac |
| Janssen Scientific Affairs, LLC | $26.10 | 2024 | Tremfya |
| Journey Medical Corporation | $21.15 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.54 | 2024 | Cyltezo |
| Promius Pharma LLC | $16.44 | 2019 | |
| Currax Pharmaceuticals LLC | $15.74 | 2025 | Contrave |
| Teva Pharmaceuticals USA, INC. | $14.61 | 2024 | Simlandi |
| Ultragenyx Pharmaceutical INC. | $11.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.